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ABSTRACT
Background: Transporter-mediated drug–nutrient interactions have
the potential to cause serious adverse events. However, unlike
drug–drug interactions, these drug–nutrient interactions receive
little attention during drug development. The clinical importance
of drug–nutrient interactions was highlighted when a phase III
clinical trial was terminated due to severe adverse events result-
ing from potent inhibition of thiamine transporter 2 (ThTR-2;
SLC19A3).
Objective: In this study, we tested the hypothesis that therapeutic
drugs inhibit the intestinal thiamine transporter ThTR-2, which may
lead to thiamine deficiency.
Methods: For this exploration, we took a multifaceted ap-
proach, starting with a high-throughput in vitro primary screen
to identify inhibitors, building in silico models to characterize
inhibitors, and leveraging real-world data from electronic health
records to begin to understand the clinical relevance of these
inhibitors.
Results: Our high-throughput screen of 1360 compounds, including
many clinically used drugs, identified 146 potential inhibitors
at 200 μM. Inhibition kinetics were determined for 28 drugs
with half-maximal inhibitory concentration (IC50) values rang-
ing from 1.03 μM to >1 mM. Several oral drugs, including
metformin, were predicted to have intestinal concentrations that
may result in ThTR-2–mediated drug–nutrient interactions. Com-
plementary analysis using electronic health records suggested
that thiamine laboratory values are reduced in individuals re-
ceiving prescription drugs found to significantly inhibit ThTR-
2, particularly in vulnerable populations (e.g., individuals with
alcoholism).
Conclusions: Our comprehensive analysis of prescription drugs
suggests that several marketed drugs inhibit ThTR-2, which may
contribute to thiamine deficiency, especially in at-risk populations.
Am J Clin Nutr 2020;111:110–121.
Keywords: drug–nutrient interactions, vitamin B1, transporters,
vitamin deficiency, clinical data, high-throughput screen, electronic
health records, machine learning
Introduction
In 2012, a phase III clinical trial involving the development
of the Janus kinase 2 (JAK2) inhibitor fedratinib was terminated
when several patients developed Wernicke’s encephalopathy
(WE) (1). WE is a serious, life-threatening neurologic condition
which occurs as a result of vitamin B1 (thiamine) deficiency
(2, 3). Following termination of the fedratinib trial, subsequent
studies indicated that fedratinib potently inhibits the primary in-
testinal absorptive transporter for thiamine, thiamine transporter
2 (ThTR-2; SLC19A3).
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Thiamine is a water-soluble vitamin that is obtained from
exogenous sources and primarily from the diet (4, 5). The
vitamin is absorbed in the small intestine via facilitated transport
and is rapidly converted via thiamine kinases into thiamine
monophosphate, thiamine pyrophosphate (TPP), and thiamine
triphosphate (6). TPP accounts for approximately 80% of total
thiamine stores in the human body and is the active form of the
vitamin, acting as a coenzyme for various enzyme complexes (6).
Membrane transporters are known sites for drug–drug inter-
actions (DDIs), especially in the small intestine, kidney, and
liver (7–9). Transporter-mediated DDIs occur when one drug
induces or inhibits a transporter, which results in a change in
the influx or efflux of another drug and potentially leads to
drug toxicities and adverse events (9, 10). As a result, DDIs are
thoroughly investigated throughout drug development and impact
drug dosing and labeling (8).
In sharp contrast, transporter-mediated drug–nutrient interac-
tions (DNIs) had been largely ignored during drug development
until the fedratinib trial. It was suggested that the toxicity
observed in this clinical trial was a result of a DNI in a population
vulnerable for thiamine deficiency, patients with myelofibrosis
(11–15). This incident raised awareness in the drug development
and regulatory communities about the potential for transporter-
mediated DNIs. Although thiamine deficiency has been primarily
associated with alcoholism, malnutrition, and various disease
states such as infection with HIV, the catastrophic event brought
to light a new mechanism for thiamine deficiency, drug-induced
deficiency (3, 5, 16–18).
Using a multifaceted approach to determine the impact and
clinical relevance of drug-induced thiamine deficiency beyond
the fedratinib trial, we were able to do the following: 1) identify
146 inhibitors of ThTR-2, some of which were predicted to cause
a DNI based on current FDA DDI guidelines, by conducting
a high-throughput screen of 1360 FDA-approved compounds,
2) elucidate key descriptors of ThTR-2 inhibition by building a
quantitative structure activity relationship (QSAR) model with
machine learning methodology which could serve as a tool for
drug discovery programs to evaluate the potential for ThTR-
2 inhibition for novel compounds, and 3) identify thiamine
deficiency in both a general patient population and in patients
who have been diagnosed with malnutrition, alcoholism, or HIV
and are taking 1 or more of the clinically relevant inhibitors
identified in our prescription drug library screen using real-world
data from electronic health records (EHRs).
Methods
Chemicals and reagents
Radiolabeled thiamine was purchased from American Radio-
labeled Chemical Incorporations. The specific activity of the
tritium-labeled thiamine hydrochloride was 20 Ci/mmol. Unla-
beled chemicals were purchased from Sigma Aldrich. Fedratinib
was purchased from Med Chem Express. Cell culture supplies
were purchased from the cell culture facility at the University
of California, San Francisco (UCSF), and Life Tech. The ThTR-
2 stable HEK 293 cell line used was created by the Giacomini
laboratory and described in Liang et al. (13). Cell lines were
obtained from −80◦C storage at the the UCSF Cell Culture
Facility for the purposes of this study. The compound library, the
USDrug Collection, was purchased fromMicrosource Discovery
Systems. The starting concentration of each drug was 10 mM in
100% DMSO.
Radiometric cell uptake screen
The ThTR-2 cell line [stably transfected HEK293 cells (13)],
was maintained in DMEM supplemented with penicillin (100
U/mL), streptomycin (100 mg/mL), puromycin (5 μg/mL),
and 10% FBS. Penicillin, streptomycin, and puromycin were
included in the growth media and removed prior to the
radiometric study. All 3 compounds were tested in our screen and
did not induce more than a 10% inhibition of thiamine uptake
compared to control. Cells were seeded at 70,000 cells per well
and cultured on poly-d-lysine–coated 96-well plates for 24 h to
reach 90% confluence. Uptake assay solutions were prepared at
2 times their final assay concentrations. The inhibitor compound
solution and the substrate (thiamine) solution were combined at
a 1:1 ratio to allow for throughput assay design. The inhibitor
compound solution was prepared by transferring 20 μL of the US
Drug Collection into 180 μL of HBSS, pH 7.4, in a 96-well plate,
producing a stock solution of 1 mM. On the day of the assay,
the compound stock solutions were used to make compound
assay solutions at a concentration of 400 μM. The thiamine
solutions were prepared at a concentration of 500 nM thiamine
hydrochloride in HBSS, with 450 nM unlabeled thiamine and 50
nM tritium labeled thiamine. The plates were designed to test
80 compounds in columns 2–11. The negative control, DMSO,
and the positive control, fedratinib, were assayed in alternating
wells in columns 1 and 12. The results from the negative control
on each plate were used to determine hits for that plate. Each
compound was tested at 200 μMagainst a thiamine concentration
of 250 nM, except for 2 of the 17 plates, for which the compounds
were screened at 500 μM. The exact concentrations of substrate,
inhibitor, and the positive control can be found in Supplemental
Table 1. To initiate the assay, the cells were washed once in 80
μL of warm HBSS, and then incubated in 80 μL of the assay
buffer at 37◦C for 5 min. Following the incubation, the cells were
washed twice with 80 μL ice-cold HBSS buffer. MicroScint-20
(Perkin Elmer) was added to the 96-well plates and sealed with an
adhesive plastic cover. Following radiometric uptake assays, the
plates were placed on a shaker overnight. The plates were read in
a MicroBeta2 (Perkin Elmer) using the dual counting mode.
Radiometric cell uptake dose–response curves
The ThTR-2 cell line was cultured in the same manner as
for the screen. Compounds selected for potency validation were
assessed in dose–response curves with concentrations ranging
from 2.5 nM to 200 μM at a substrate concentration of 250 nM
thiamine. The compound and substrate buffers were made at 2
times their assay concentration and then combined at a 1:1 ratio
to reach the final assay concentrations as in the primary screen.
The compound buffer was made by serial dilutions in HBSS.
The substrate buffer was made with 450 nM unlabeled thiamine
and 50 nM tritium-labeled thiamine, which was subsequently
diluted to reach final thiamine concentrations of 225 nm
unlabeled thiamine and 25 nM tritium-labeled thiamine. Each
plate contained control wells with no inhibitor which were used
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for normalization in data analysis. To initiate the assay, the cells
were washed once in 80 μL warm HBSS, and then incubated
in 80 μL of the assay buffer at 37◦C for 5 min. Following the
incubation, the cells were washed twice with 80 μL ice-cold
HBSS buffer. MicroScint-20 (Perkin Elmer) was added to the 96-
well plates and sealed with an adhesive plastic cover. Following
radiometric uptake assays, the plates were placed on a shaker
overnight. The plates were read in a MicroBeta2 (Perkin Elmer)
using the dual counting mode.
Data analysis for radiometric cell uptake assays
Hit calling for the primary screen was conducted and Z-prime
scores were calculated within each plate using the positive and
negative controls (19). The mean ± SD of the vehicle negative
control for each plate was determined and all compounds were
normalized to this control. A hit threshold was set as 3 SDs below
the average of the negative control respective to each plate. Com-
pounds were classified as hits if they were below this cutoff. All
the hits and nonhits from each plate were compiled together and
the normalized values were plotted (with respect to plate) using
ggplot. Data from half-maximal inhibitory concentration (IC50)
curves were exported to Excel for normalization and entered into
GraphPad Prism 8.0 for graphing and nonlinear fitting.
Clinical relevance ratios
One-point thiamine inhibition values for each compound
from the primary screen were used in combination to de-
termine the predicted IC50 (prIC50) (20) with the equation
V = V0/{1 + [(I)/prIC50]}, where V and V0 are the activity
with and without inhibitor, respectively, and I is the inhibitor
concentration of 200 μM. Dosing information for each of the
primary screen hit compounds was reviewed from the clinical
databases IBM Micromedex and Lexicomp, and a maximal
reported single dose was documented. The maximal intestinal
concentration for each drug was determined by dividing the
maximal dose by 250 mL (21). A ratio was calculated using the
prIC50 and the maximal intestinal concentration.
Data preparation for the QSAR model
Compound names (n = 1360) were used as queries to the
PubChem database (22) to retrieve compound identification
numbers and structure data files (SDFs). Four compounds were
removed due to failure to compute SDF files. SDF files were
processed with PaDEL software (23) to compute 770 molecular
descriptors for each screened compound. Molecular descriptors
were filtered to remove descriptors with missing values (n= 595)
and descriptors with zero variance (n = 60). To identify highly
correlated features (correlation coefficient >0.95), pairwise
descriptor correlations were computed and, from each highly
correlated pair, 1 randomly chosen feature was removed (n= 41),
leaving 74 molecular descriptors for 1356 compounds. Feature
selection was implemented using the caret R package (24).
Correlation-based feature selection was performed, in which a
greedy heuristic is employed to pick a subset of features that are
independent of each other but are correlated with a class label
(25). In vitro screening data were used to label 144 compounds
as hits (label = 1) and 1212 as nonhits (label = 0).
Analysis of physicochemical properties for QSAR model
MayaChemTools package (26)was used to compute 8 physico-
chemical descriptors, namely, molecular weight, molecular vol-
ume, number of rotatable bonds, number of heavy atoms, number
of hydrogen bond donors and acceptors, octanol–water partition
coefficient (SLogP), and total polar surface area. Distributions of
physicochemical properties for hit and nonhit compounds were
analyzed in the R statistical package. Pairwise Student’s t test was
performed, using t.test in R, for the 8 physicochemical properties
to identify those that differed significantly. Results were plotted
using the boxplot function in R.
QSAR model development with machine learning
Four machine learning algorithms from the caret package in R
(k-nearest neighbors, partial least squares regression discriminant
analysis, support vector machine, and random forest), were
employed to build binary classifiers. A double loop cross-
validation (20) was used to assess the predictive power of each
algorithm. First, the train function in the caret R package was
used to fit predictive models for the 4 algorithms for 75% of
the original data (training data set; n = 1017). Parameter tuning
was done with 10-fold cross-validation as follows. The training
set was divided into 10 subsets with each subset comprising the
same ratio of hits (∼90%) and nonhits (∼10%) as the original
data set. Model parameters were optimized by fitting classifiers
to 9 out of 10 subsets and assessing them with the 1 out of
10 subsets. Next, the performance of each tuned model was
assessed on 25% of the data (holdout set; n = 340) using the
area under the receiver operating characteristic curve (auROC)
(27) as the performance measure. Double-loop cross-validation
was repeated 10 times for both full and reduced feature sets.
First, classifiers were built with 74 molecular descriptors (full
feature set). Second, feature reduction was performed with the
cfs filtering algorithm in the FSelector R package for each of
the training data sets. We identified a subset of 18 features that
overlapped between different training sets to create a reduced
feature set. Finally, cross-validation of models trained with these
18 features was performed. ROC curves were plotted with the
ROCR package in R (28).
Substructure similarity search
The ChemBioServer web service (29) was used to search
for compounds containing fragments similar to the 2,4-
diaminopyrimidine fragment. To that end, the structure of 2,4-
diaminopyrimidine in SDF format was queried against the 1356
SDF files using an online interface with default settings.
EHR data and analysis
We used the UCSF Research Data Browser to search for
patients who had a reported numeric thiamine pyrophosphate
laboratory (measured in whole blood by the UCSF Health
Clinical Laboratories) test value<1200 nM, which gave us a total
of 1433 patients and 2016 laboratory values. Thiamine laboratory
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values reported as <7 nM were assigned the value of 0 nM. Only
patients with 1 thiamine laboratory value were included in the
analysis, which reduced our sample size to 1133 individuals.
Patients were divided into 2 groups depending on their
medication use. Patients prescribed 1 or more of the orally
dosed drugs that were identified as potentially clinically relevant
hits in the primary screen and analysis (metformin, verapamil,
amitriptyline, sertraline, amoxapine, pencillamine, quinidine,
quinapril, and/or hydroxychloroquine) were grouped into the
“on” drug group, which resulted in 236 patients. In addition,
sulfamethoxazole-trimethoprim was an inclusion criterion for
the on group only in the HIV analysis since this drug is not
chronically taken among the general population but can be
chronically used in HIV patients as a prophylaxis for pneumonia.
Fedratinib was not included in any of the analyses since it was
not an approved therapeutic agent. The 897 remaining patients
(i.e., individuals who were never prescribed any of the clinical
hits mentioned above) were grouped into the “off” drug group.
Patients in the on group were further filtered based on their
laboratory collection date relative to their first medication order
start date. Thiamine laboratory values measured before the on
group patient’s first medication order start date or within 30 d
after their first medication order start date were excluded. A
minimum of 30 d between medication start date and the thiamine
laboratory value measurement was chosen since it can take a few
weeks for thiamine stores to deplete. In total, 155 patients met
this criterion and were in the on group.
For patient population–specific analyses, patients were further
assigned to subgroups based on a diagnosis of malnutrition,
alcoholism, or HIV. Malnutrition diagnosis was defined using the
International Classification of Diseases (ICD) as ICD10 level 1
“endocrine, nutritional and metabolic diseases” (E00–E89) and
ICD10 level 2 “malnutrition” (E40–E46). Alcoholism diagnosis
was defined as ICD10 level 3 “alcohol related disorders,”
“alcoholic liver disease,” “evidence of alcohol involvement
determined by blood alcohol level,” and “toxic effect of alcohol.”
HIV diagnosis was defined as ICD10 level 1 “certain infectious
and parasitic diseases (A00-B99)” and ICD10 level 2 “human
immunodeficiency virus [HIV] disease.” There were 221, 121,
and 19 patients with 1 reported thiamine laboratory value and
a malnutrition, alcoholism, and HIV diagnosis, respectively,
without any regard to medication use. Patients which met the
inclusion criteria for 2 or more diagnoses were included in both
patient population-specific analyses.
We further subdivided the patient groups in each respective
patient population based on their laboratory collection date
relative to their first diagnosis date. Laboratory values taken any
time before diagnosis were considered for patients diagnosed
withmalnutrition. For patients with alcoholism, laboratory values
taken within 1 year of diagnosis were used. Lastly, for patients
diagnosed with HIV, laboratory values taken 1 year prior to or any
time after diagnosis were considered. This resulted in 45 patients
with malnutrition, 76 patients with alcoholism, and 16 patients
with HIV before filtering for medication use/prescriptions was
performed. The total number of patients in the on and off
groups after filtering based on medication order start date and
prescriptions is listed in the Results section. All analyses were
performed relative to only the date of initial diagnosis, laboratory
value collection dates, and medication start dates; no other
covariates were included in the analysis.
Welch’s 2-sample t-test was performed to evaluate if there
was a significant difference in laboratory values when comparing
both groups and ggplot was used to plot the data using R
(version 3.4.0).
Results
Overview
The overview of our study design is presented in Figure 1.
Our first goal was to perform a cell-based high-throughput screen
to identify prescription drugs and other bioactive compounds
that inhibit ThTR-2. Using the data from the primary screen,
we validated a subset of the most potent compounds as well
as investigated several drugs to assess their potential to cause
clinically relevant DNIs at ThTR-2 (Figure 1B). Additionally,
we leveraged computational methods to identify features specific
to hits and nonhits from our screen. To complement our
screen and model, we investigated and compared thiamine
laboratory values in patient populations that are prone to thiamine
deficiency. Specifically, we compared thiamine pyrophosphate
plasma concentrations from patients taking 1 or more of the
clinically relevant inhibitors that had been identified in our high-
throughput screen with concentrations from patients who were
not on any of those inhibitors. Our goal here was to explore
the hypothesis that these inhibitors may exacerbate thiamine
deficiency in vulnerable populations.
In vitro radiometric thiamine inhibition screen identified
146 potential thiamine inhibitors
A radiometric screen to identify marketed drugs that inhibit
ThTR-2–mediated thiamine uptake was performed using tritium-
labeled thiamine hydrochloride. Prior to the screen, the optimal
conditions for thiamine uptake in cells overexpressing ThTR-
2 were determined (i.e., duration of uptake, concentration of
thiamine, and plating density of cells, see the Methods section).
Most compounds were screened once in a 96-well plate using
a 5-min uptake assay. To determine the inhibitor concentration
to use for the screen, the single maximum doses for commonly
prescribed drugs were collected and used to predict intestinal
concentrations (Supplemental Figure 1). This informal in silico
review guided the selection of the final drug concentration of
prescription drugs and other compounds in the library (200 μM)
used in the primary screen.
The drug library used for the primary screen comprised 1360
diverse compounds with various mechanisms of action and from
many therapeutic classes (Figure 2). Inhibitors, or hits, were
defined by a decrease in thiamine uptake greater than 3 SDs from
the thiamine only (no inhibitor) control (Supplemental Figure
2). Slight enrichment of hits was seen in certain therapeutic
classes, including drugs used in the treatment of gastrointestinal
and central nervous system disorders (Figure 3). Out of the
1360 compounds screened, 146 were determined to be ThTR-2
inhibitors (z-prime: 0.44–0.81) (Supplemental Table 1) (19).
Potency studies of top inhibition hits validate primary screen
As the primary screen was conducted with single point
determinations, the top 11 compounds, based on percentage
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FIGURE 1 Workflow of experimental and computational methods for primary screen and identification of clinically relevant hits. Schematic of workflow
used to identify, validate, and determine the potential clinical relevance of ThTR-2 inhibitors (A). Shown on the left are the 4 major stages to identify marketed
drug inhibitors of ThTR-2. These major stages are accompanied by substages of each effort (on the right) with the selection criteria in the colored box and
the number of compounds selected for progression to the next stage below each colored box. Detailed methods used to select compounds at each stage can
be found in the Methods section. Detailed workflow used to identify and validate clinically relevant hits (B). Parallel steps were applied to the hits identified
from the primary screen to determine the clinical relevance and potential to cause a drug–nutrient interaction. The number of compounds entering each step is
noted above and the criteria that filtered that collection of compounds is summarized in the box below it. ∗12 compounds were validated using experimental
IC50 values and 2 compounds (metformin hydrochloride and trimethoprim) were validated using literature derived IC50 values (12, 13). IC50, concentration
which causes 50% inhibition of uptake; pr[I], predicted inhibitor concentration in the small intestine following maximum single dose; ThTR-2, thiamine
transporter 2.
inhibition of 3H-thiamine uptake, were selected to test in 8-point
dose response curves to validate the accuracy of the primary
screen. Ten of the 11 compoundswere validated as hit compounds
(Supplemental Table 2). Citric acid was determined to be a false
positive. In general, the 10 validated hits have IC50 values, the
half-maximal inhibitory concentration, <100 μM (Figure 4A
and Supplemental Figure 3). Additionally, randomly selected
compounds that were identified as noninhibitor compounds were
also tested and confirmed to not inhibit the transporter.
Selected clinically relevant screen hits maintain predicted
potency
As screening of the top hit compounds validated the primary
screen, a clinical relevance ratio, calculated using the predicted
intestinal concentration following a single dose divided by the
IC50, was employed to identify which of the 146 hits from the
primary screen would be clinically relevant. These compounds
were chosen based on their clinical relevance ratios (≥10),
availability in oral dosage forms, chronic dosing schedules, which
could result in prolonged inhibition of intestinal ThTR-2, and
use in patient populations at-risk for thiamine deficiency. Of
the 146 hits, 88 were orally administered drugs. Out of the 88
orally administered compounds, 10 compounds were selected for
further validation by utilizing the additional selection criteria,
noted above (Supplemental Table 3). Of the 10 compounds,
5 were identified as potent inhibitors of ThTR-2 with low
nanomoles per liter IC50 (Figure 4B and Supplemental Figure
4). Five inhibitors with predicted clinical relevance, and 3 of
the other selected inhibitors, despite higher IC50 values, were
estimated to reach intestinal concentrations 10 times greater than
their IC50 values, suggesting the potential to cause a DNI at
ThTR-2 (Table 1 and Figure 1B).
Computational characterization of properties of hit
compounds
We used several methods to characterize and differentiate
properties of hit and nonhit compounds identified by high-
throughput screening.
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FIGURE 2 Classification of drug library by therapeutic class. The US
drug collection library used for the high-throughput screen comprised a
diverse set of compounds which ranged across various pharmacological
classes. CNS, central nervous system.
First, we computed and analyzed 8 physicochemical properties
of hits and nonhits, such as molecular weight, molecular
volume, number of heavy atoms, number of rotatable bonds,
number of hydrogen bond donors and acceptors, SLogP, and
topological polar surface area (Table 2 and Supplemental
Figure 5). No statistical differences were observed in molecular
weight, volume, number of heavy atoms, or number of rotatable
bonds. The values for the number of hydrogen bond donors
and acceptors and total polar surface area were significantly
lower among hit compared to nonhit compounds (P < 0.0001).
Moreover, hit compounds were more lipophilic as evidenced by
significantly higher SLogP values (P < 0.0001) compared to
those of nonhits.
Second, we developed machine learning classifiers to dif-
ferentiate between hit and nonhit compounds from the high-
throughput screen. The performance of 4 machine learning
algorithms was estimated by means of double-loop cross-
validation, consisting of internal 10-fold cross-validation and
external validation using 10 test sets consisting of 25% of
samples (see Methods section). We evaluated 4 machine learning
algorithms, namely k-nearest neighbors, partial least squares
regression discriminant analysis, support vector machines, and
random forest (RF). For each algorithm, we trained each classifier
with 770 and 18 molecular descriptors, respectively. The 18
descriptors were identified via a recursive feature selection
method (Supplemental Table 4). These descriptors represent a
common subset of features selected from different training sets
during the cross-validation. The receiver operating characteristic
(ROC) curves for external validation experiments of 4 algorithms
are shown in Supplemental Figure 6A for 18 features and
in Supplemental Figure 6B for 770 features. The RF classifier
outperformed the other 3 models as assessed by the average
auROC for the 10 external validation tests. Performance of all
models was considered better than random. Notably, the auROC
of RF classifier with 770 features was 0.71 ± 0.03 and with
18 features 0.74 ± 0.05, respectively. The performances of
the other models, though slightly worse than that of the RF
model (Supplemental Figure 6A), improved with use of the
18 descriptors over the full 770 features (Supplemental Figure
FIGURE 3 Total number of hits and nonhits in each therapeutic class. Although the diversity of the hits trended similarly to the diversity of the prescription
drug library, there was enrichment of certain pharmacological classes such as drugs used in the treatment of gastrointestinal and CNS disorders. Numbers above
bars represent raw count of hits and non-hits in each therapeutic class respectively. Percent represents enrichment of hits in a therapeutic class (i.e., hits which
fall in a class/total number of compounds in that same class). CNS, central nervous system.
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FIGURE 4 IC50 curves of a subset of (A) potent and (B) clinically relevant hits. IC50 values were determined for selected drugs in HEK293 cells stably
overexpressing ThTR-2. Eight-point curves were conducted on 96-well plates with inhibitor concentrations ranging from 200 μM to 2.5 nM and 250 nM
thiamine. Data points and error bars are presented as means ± SEMs, respectively. Each curve is representative of 3 experiments and each concentration was
tested in duplicate within each experiment. IC50 values range from 2.56 to 100 μM in panel A and 1.03 to 4.04 mM in panel B and are listed in detail in
Supplemental Tables 2 and 3. IC50, concentration which causes 50% inhibition of uptake; ThTR-2, thiamine transporter 2.
6B). Analysis of the 18 selected features revealed that the
lipophilicity, descriptors of topological and chemical diversity,
and descriptors of hydrogen bond counts were important for the
accuracy of differentiating between hit and nonhit compounds.
More specifically, the number of nitrogen atoms and number of
CrippenLogP descriptors were ranked as the 2 most important
descriptors for the RF classifier (Supplemental Table 4). Four
discrepancies in hit calling between screen and the RF QSAR
TABLE 1 Prescription drug inhibitors predicted to be clinically relevant based on experimental and computational
methods1
Drug name
Max single dose,
mg
IC50,
μM
[Predicted
Intestinal]/IC50
DDI study
recommended2
Trimethoprim3 320 5.6 ± 0.59 793 Yes
Fedratinib 500 7.50 ± 0.883 600 Yes
Hydroxychloroquine sulfate 400 17.0 ± 5.24 217 Yes
Sertraline hydrochloride 200 1.03 ± 0.255 201 Yes
Amitriptyline hydrochloride 100 11.3 ± 2.85 116 Yes
Metformin hydrochloride3 2500 680 ± 372 88.8 Yes
Amoxapine 300 46.6 ± 14.7 81.4 Yes
Penicillamine ethanolamine salt 2000 857 ± 372 62.6 Yes
Verapamil 480 141 ± 46 27.7 Yes
Quinidine gluconate 648 181 ± 52.8 27.5 Yes
Quinapril 80 34.0 ± 7.36 19.8 Yes
Didanosine 400 4040 ± 5740 8.29 No
Posaconazole 400 1896 ± 1767 1.80 No
Telmisartan 160 Not convergent — No
1Based on the workflow detailed in Figure 1B, 14 compounds were predicted to be clinically relevant hits and
selected for further validation. Hit inhibitors were defined as clinically relevant if the ratio of the compound’s
predicted intestinal concentration (following maximum single dose given at one time) divided by its IC50 was >10.
DDI, drug–drug interaction; IC50, half maximal inhibitory concentration; [Predicted Intestinal], predicted intestinal
concentration.
2A subset of these compounds would be recommended for a DDI trial based on current FDA guidelines.
3Trimethoprim and metformin hydrochloride IC50 values were obtained from published literature (12, 13).
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TABLE 2 Physicochemical descriptors of hit and nonhit compounds
identified in a screen of ThTR-21
Descriptor Hits Nonhits P value
Molecular weight (Da) 330 ± 116 343 ± 194 2.24 x 10-1
Molecular volume (A˚3) 304 ± 105 309 ± 180 6.14 x 10-1
Heavy atoms (n) 23.0 ± 8.02 23.5 ± 13.3 4.51 x 10-1
Rotatable bonds (n) 5.07 ± 4.35 5.05 ± 4.50 9.60 x 10-1
Hydrogen bond donors (n) 1.06 ± 1.13 2.04 ± 2.42 1.04 x 10-15
Hydrogen bond acceptors (n) 4.32 ± 2.70 5.96 ± 4.60 1.19 x 10-9
SLogP 4.02 ± 1.90 2.90 ± 2.44 6.48 x 10-10
Total polar surface area (A˚2) 56.1 ± 42.2 88.5 ± 74.3 7.57 x 10-14
1Mean ± SD values for 8 physicochemical descriptors are shown for
144 hits and 1213 nonhits. P < 0.005 for differences in distributions of
physicochemical properties of hits compared with those of nonhits,
estimated with the Student’s pairwise t-test. SLogP, log of the octanol–water
partition coefficient, including implicit hydrogens; ThTR-2, thiamine
transporter 2.
model were observed (Supplemental Tables 5 and 6). To
analyze the tradeoff between the precision and recall of the
RF classifier with 18 features, we computed the average F1
measure, which was 0.58. The average precision and recall were
0.7 and 0.5, respectively. The lower recall indicates that the
model is less successful at filtering out false negatives than false
positives.
EHRs validate identified clinically relevant inhibitors
To investigate the clinical relevance of the inhibitors identified,
we mined EHRs from UCSF and identified drug-induced
decreases in thiamine laboratory values associated with the use of
the drugs identified in our screen in both the general population
and distinct patient populations. Specifically, we compared
thiamine laboratory values in patients prescribed 1 or more of
the 9 (10 for HIV patients) clinically relevant inhibitors identified
in the primary screen (Table 1) with thiamine laboratory values
in patients who were never prescribed any of the respective
inhibitors. Based on the inclusion and exclusion criteria described
in the methods, we were able to classify patients as “on” drug
(i.e., on 1 or more of the clinically relevant inhibitors) or “off”
drug.
In the general population, we observed a significant difference
in thiamine laboratory values between the 2 groups (P = 0.02;
n = 154 on drug; n = 878 off drug). If we add thiamine
medication orders as an exclusion criterion, we still observed a
significant difference (P = 0.003) in thiamine laboratory values
between the on drug (n = 36) and off drug (n = 215) groups,
demonstrating the robustness and sensitivity of our analysis.
Population demographics, such as age and sex, as well as
number of medication orders based on unique pharmaceutical
class (i.e., each pharmaceutical class is counted only once per
patient irrespective of number of prescriptions), were comparable
between both groups (Supplemental Table 7).
Three distinct patient populations: malnourished, alcoholic,
and HIV patients, which have been associated with thiamine
deficiency (3, 5, 16–18), were used to further investigate and
elucidate drug-induced decreases in thiamine laboratory values.
In all 3 patient populations, patients in the on drug group had
lower thiamine pyrophosphate blood concentrations than those
in the off drug group (Figure 5). In malnourished patients,
when comparing thiamine laboratory values from samples taken
any time before diagnosis, we observed lower concentrations of
thiamine pyrophosphate for individuals on drug (n = 8) than
individuals off drug (n = 30) at a statistically significant level
(P = 0.015) (Figure 5A). In patients diagnosed with alcoholism,
there were significantly lower concentrations (P = 0.000002) in
the on than the off drug groups when we compared thiamine
laboratory values taken within 1 y of diagnosis (n = 2 on drug;
n= 68 off drug) (Figure 5B). Lastly, although we did not observe
a significant difference between the 2 groups in HIV patients
when including thiamine laboratory values taken within 1 y
before diagnosis or any time after diagnosis (P = 0.20; n = 9
on drug; n = 4 off drug), we still observed lower thiamine
laboratory values in on patients compared to off patients, which
was consistent with our other patient populations (Figure 5C).
If we combine all 3 patient populations with the same inclusion
and exclusion criteria used in the individual analyses, we observe
a statistically significant difference, as previously observed (P =
0.0004; n = 18 on drug; n = 96 off drug) (Figure 5D).
Finally, if we added thiamine medication orders (i.e., pre-
scribed thiamine or vitamin B1 supplements and/or given
thiamine intravenously) as an exclusion criterion, we still
observed a significant difference between the 2 groups (on drug
and off drug) in the alcoholic patient population (P= 0.00008 for
laboratory values within 1 y of diagnosis, n = 2 on drug, n = 24
off drug) and we still observed a downward trend inmalnourished
and HIV patients; that is, thiamine laboratory values were lower
in malnourished and HIV patients on a ThTR-2 inhibitor than
in those not on a ThTR-2 inhibitor (P = 0.056 and P = 0.27
respectively).
Discussion
DDI studies are a routine and necessary component of clinical
drug development. In contrast, DNI studies are rarely performed.
The clinical trial of fedratinib, with the development of WE in
a handful of patients, underscored the importance of DNIs and
the effect of drugs on transporter-mediated nutrient absorption in
clinical drug development (1, 30, 31). The current study explored
the idea that DNIs mediated by intestinal ThTR-2 occur with
clinically used drugs and that such interactions may contribute
to thiamine deficiency, especially in vulnerable populations.
This study resulted in 4 major findings, and highlighted
the potential for commonly prescribed drugs to contribute to
thiamine deficiency. First, we identified many prescription drug
inhibitors of ThTR-2–mediated thiamine uptake, representing a
surprising fraction (approximately 10%) of the prescription drug
library that was screened. Second, 4 key molecular descriptors
were identified that can aid in distinguishing ThTR-2 inhibitors
from noninhibitors, including increased hydrophobicity, lower
polar surface area, and reduced ability to form hydrogen
bonding as acceptors or donors. Third, many of the prescription
drug ThTR-2 inhibitors are predicted to inhibit intestinal
ThTR-2–mediated thiamine absorption at clinically relevant
intestinal concentrations. Finally, a thiamine deficient signature
was observed in patients diagnosed with HIV, malnutrition,
and alcoholism taking 1 or more of the drugs predicted
to inhibit intestinal ThTR-2–mediated thiamine uptake. The
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FIGURE 5 Thiamine laboratory values in patients on 1 or more clinically relevant inhibitors compared with concentrations in patients in vulnerable
populations but not on a clinically relevant inhibitor. Boxplots of thiamine laboratory values in malnourished, P = 0.015 (A); alcoholic, P = 0.000002 (B);
and HIV, P = 0.20 (C) patients, as well as all 3 patient populations combined, P = 0.0004 (D), comparing laboratory values of individuals on 1 or more of
the clinically relevant inhibitors identified in the primary screen with patients who were not. Inhibitors are noted in Table 1 (based on the DDI recommended
column). ∗P ≤ 0.05, ∗∗∗P ≤ 0.001 following a Welch’s 2-sample t-test. Sulfamethoxazole-trimethoprim was an inclusion criterion for the on group only in the
HIV analysis since this drug is not chronically taken among the general population but can be chronically used in HIV patients as a prophylaxis for pneumonia.
DDI, drug–drug interaction.
results suggest the potential of these drugs to cause DNIs and
contribute to thiamine deficiency and WE in susceptible patient
populations.
Thiamine deficiency has been repeatedly associated with a
cascade of events linked to cognitive decline, many of which
are commonly observed in Alzheimer disease and Parkinson
disease, where thiamine has been suggested as a potential
therapeutic modality (32–36). Thiamine deficiency is a treatable
condition when recognized, as seen in global populations where
malnutrition is a major concern (37–40). Additionally, the
dire consequences of thiamine deficiency have repeatedly been
observed in children of developing countries where thiamine
deficiency disorders, often triggered by infectious diseases,
are a major cause of infant mortality (41–46). Though severe
outcomes of thiamine deficiency can lead to a clear diagnosis,
mild to moderate thiamine deficiency symptoms are frequently
overlooked or misdiagnosed (3, 18, 47–51). Furthermore, even in
conditions known to predispose patients to thiamine deficiency,
the variability in the presentation of the disorder suggests that un-
known confounding factors may also contribute to the deficiency
syndrome. Unfortunately, recent studies echo the complexity
of recognizing thiamine deficiency and suggest that thiamine
deficiency even in developed countries is underdiagnosed and
undertreated (52–54). Unrecognized thiamine deficiency is a real
problem as the neurologic sequelae may increase the burden
on healthcare systems and reduce the general health of world
populations.
This study represents 1 of the first studies to evaluate the broad
potential of approved drugs to contribute to nutrient deficiency
syndromes, and to our knowledge, is 1 of the first high-throughput
in vitro screens for ThTR-2. Hit compounds from our primary
screen did not show enrichment for any 1 therapeutic class,
suggesting that drug–thiamine interactionsmay occur across drug
classes. The broad inhibitor specificity identified in this study is
consistent with recent studies from our laboratory, which have
indicated that human ThTR-2 may be more promiscuous in terms
of its substrate selectivity than rodent orthologs, which narrowly
transport thiamine (13).
Previous studies have indicated that ThTR-2 inhibitors share a
common structural feature, a 2,4-diaminopyrimidine, specifically
within the Janus kinase inhibitor class (11, 12). To assess if
ThTR-2 inhibition could be caused by compounds without this
structure, we utilized a diverse compound library. Preliminary
computational analysis of our screen results revealed that
inhibitors were significantly smaller, less polar, and more
hydrophobic. Prediction of a compound’s inhibitory potential
based on these broad molecular descriptors alone would be
difficult given the large molecular and structural diversity of
our library and would likely result in many false positives.
Therefore, we attempted to use machine learning and the
identified descriptors to build models that may more reliably
predict compounds that may inhibit the transporter. The models
built with the RF algorithm performed better than random, as
determined by the cross-validated auROC of about 0.7. Our RF
model differs from published computational models that predict
drug–food interactions and/or food bioactivities in that it aims to
identify properties of molecules that inhibit ThTR-2 andmay lead
to thiamine deficiency (55).
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The aim of this study was not only to assess the extent to
which ThTR-2 may be inhibited by marketed prescription drugs
but to also determine their potential to contribute to thiamine
deficiency clinically. Current FDA DDI guidelines provide a
ratio, previously described in the Methods sections, for which
>10 indicates a dedicated healthy volunteer DDI study may
be warranted (21). Eleven of the 14 selected orally prescribed
drugs were predicted to reach this benchmark, by estimating the
ratio of predicted intestinal concentration following maximum
single dose to experimental IC50, suggesting that they may
result in clinically relevant inhibition of ThTR-2. Metformin
was among the drugs deemed clinically relevant and mirrored
previous suggestions about its ability to cause DNI at ThTR-2
(13). Additionally, some of the clinically relevant drugs identified
in our study are used chronically in patients who may already be
at risk for thiamine deficiency (56–64).
By examining the EHRs for patients at risk for thiamine
deficiency, we were able to use real world data to support the idea
that prescription drugs may contribute to thiamine deficiency,
and indeed may be major risk factors for WE or beriberi
in vulnerable populations. Additionally, inhibition of ThTR-2
may contribute to adverse events associated with some of the
therapeutics. For example, a common adverse event associated
with metformin use is lactic acidosis (65), a potentially fatal
adverse event also associated with thiamine deficiency. If, as our
results suggest, metformin inhibits intestinal ThTR-2–mediated
thiamine transport, the resulting low concentrations of thiamine
and TPP could contribute to metformin-induced lactic acidosis
(18, 50, 66–68).
The limitations of this study include the high concentrations
used in the initial screen, which were much higher than
concentrations used in typical drug discovery screens (69–
71). A high screening concentration was used to reflect the
concentrations predicted to be achieved in the intestine after
therapeutic doses of drugs. Another limitation of the high-
throughput screen was that each compound was evaluated in
a single well. This approach was taken due to the fact that
no fluorescent probe was available and may have resulted in
false negatives. Another limitation was the performance of
the machine learning classifier, which was constrained due to
the large structural diversity of the compound library, limited
number of compounds (<2000), and lack of novel molecular
structures currently in development. Screening a larger library
with many molecules having particular structural backbones may
help refine the structure–activity relationships as well as improve
the prediction capability of the model. Furthermore, although we
used FDA guidance as a benchmark to select compounds which
have the potential to cause clinically relevant DNIs, this guidance
is meant for drugs and not nutrients and for efflux transporters
(and not influx transporters) that are targets for DDIs. Since
inhibition of efflux transporters requires inhibitors to access the
intracellular compartment, which is not required for inhibition
of an influx transporter, the guidelines may have been overly
stringent for our study. In addition, our EHR analysis was limited
by small sample sizes. Finally, the use of publicly available
data rather than a designated clinical trial allowed us to show
an association between these drugs and low thiamine laboratory
values but prevented us from differentiating between the role of
disease and role of the drug, assessing the effect of nutritional
status on thiamine laboratory values, and determining whether
these drugs inhibit intestinal ThTR-2–mediated thiamine uptake.
Additional samples or designated clinical studies powered to
detect drug-related differences as well as assess nutritional status
are needed to make broader conclusions.
Overall, our comprehensive study was able to identify 146
inhibitors of ThTR-2, most of which were not previously known.
These compounds aided in elucidating structural and chemical
features of ThTR-2 inhibitors and, though further screens are
needed, provided a preliminary in silico model for identifying
compounds that inhibit ThTR-2. Compounds that may cause
clinically relevant drug–nutrient interactions were predicted, and
real-world data from the EHR in vulnerable patient populations
were consistent with our predictions. Future work includes
investigating the effects of ThTR-2 genetic variants on the plasma
concentrations of both thiamine as well as prescription drugs,
and conducting prospective DNI studies of prescription drugs
and thiamine. This study has led to the largest available dataset
of ThTR-2 inhibitors and underscores the potential importance
of drug–nutrient interactions at ThTR-2 as well as other vitamin
transporters.
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